BioPorto A/S to host an investor webcast on the results for the first half of 2025

About this update from Bioporto A/s

[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XFhYiV2fxrmNbtDA3N3v_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"  ","length":12,"tagName":"p"},{"type":"text","content":"July 29, 2025","length":13,"tagName":"p"},{"type":"text","content":"News release","length":12,"tagName":"p"},{"type":"text","content":"BioPorto A/S to host an investor webcast on the results for the first half of 2025 ","length":82,"tagName":"p"},{"type":"text","content":"COPENHAGEN, DENMARK, July 29, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CFO Niels Høy Nielsen will present financial results for the first half of 2025 at a webcast for investors on August 15 at 11:00 AM CET.","length":264,"tagName":"p"},{"type":"text","content":"Registration for the presentation is now open, and participants can submit questions in advance. Please register at the following link: https://www.inderes.dk/videos/bioporto-praesentation-af-halvarsregnskabet-for-2025","length":218,"tagName":"p"},{"type":"text","content":"For further information, please contact:","length":40,"tagName":"p"},{"type":"text","content":"Hanne S. Foss, Head of Investor Relations, BioPorto A/S, [email protected], C: +45 26368918","length":95,"tagName":"p"},{"type":"text","content":"About BioPorto","length":14,"tagName":"p"},{"type":"text","content":"BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.","length":574,"tagName":"p"},{"ty...

More updates from Bioporto A/s